Press Release & Update

2024/03/28
Press Release: Marketing Authorization Application of Intranasal Influenza Vaccine (BK1304)
2024/03/15
Press Release: Launch of “GOBIK Aqueous Suspension Syringes”, Pertussis, Diphtheria, Tetanus, Inactivated Polio and Hib Combined Vaccine
2024/01/23
Press Release: Co-promotion of “GOBIK Aqueous Suspension Syringes”, Pertussis, Diphtheria, Tetanus, Inactivated Polio and Hib Combined Vaccine
2023/09/27
Press Release: VLPT Japan, Biken Foundation, Denka sign agreement to develop self-amplifying “replicon” RNA influenza vaccine
2023/09/14
Press Release: VLPT Japan, Biken Foundation sign MoU on potential business alliance eying 2023 conclusion of “replicon” RNA COVID-19 vaccine production, sales license agreement
2023/06/19
Notice: Announcement of BIKEN Group’s new board members
2023/03/27
Press Release: Approval of “GOBIK Aqueous Suspension Syringes”, Pertussis, Diphtheria, Tetanus, Inactivated Polio and Hib Combined Vaccine
2022/04/11
Press Release: Marketing Authorization Application of Pertussis, Diphtheria, Tetanus, Inactivated Polio and Hib Combined Vaccine (BK1310/MT-2355)
2019/11/11
Press Release: Regarding the Incident of Vaccine Culture Fluid Leakage at Seto Office
2017/05/09
Press Release: Establishment of Vaccine Manufacturing Joint Venture: BIKEN Co.,Ltd.
2016/11/08
Press Release: Basic Agreement on the Establishment of a Joint Venture
2016/09/06
Press Release: BIKEN begins development of Zika virus vaccine, upon concluding agreement on virus distribution with Chiba Prefectural Institute of Health
2016/06/30
Notice: BIKEN additionally supports recovery efforts from The 2016 Kumamoto Earthquake
2016/04/26
Press Release: BIKEN supports recovery efforts from The 2016 Kumamoto Earthquake
2016/04/05
Update: The page of Research & Development is released.
2016/04/01
Press Release: Biken joins the Japan Pharmaceutical Manufacturers Association
2016/04/01
Press Release: Announcement of Organizational Changes and Personnel Changes
2015/12/21
Update: We have posted our new foundation brochure.
2015/04/06
Press Release: BIKEN Enters into a License Agreement with Osaka University for the Development of a New Pneumococcal Vaccine